2012-2014 Master's in Public Health with Focus in Biostatistics, Harvard School of Public Health, Boston MA
1999-2004 Medical Doctorate with Distinction in Research, Albert Einstein College of Medicine, Bronx NY
1992-1996 Bachelor of Science - Chemistry, University of Idaho2012-2013 Fellow in Research, Harvard School of Public Health, Boston MA
2011-2012 Interventional Pulmonary Fellow, Massachusetts General Hospital/Beth Israel Deaconess Medical Center, Boston MA2009-2011 Pulmonary and Critical Care Fellow, Massachusetts General Hospital, Boston MA
2008-2009 Chief Medical Resident, Beth Israel Deaconess Medical Center, Boston MA
2005-2007 Resident, Internal Medicine, Beth Israel Deaconess Medical Center, Boston MA
2004-2005 Intern, Internal Medicine, Beth Israel Deaconess Medical Center, Boston MA
Dr. Kinsey directs an NIH funded research program focused on developing personalized approaches for both understanding lung cancer risk and the development of therapies for lung cancer. We currently focus on two specific areas where we could potentially improve care for patients.
The vast majority of nodules detected on a CT scan of the chest are not cancer but the risk of not treating a cancer found on CT is obviously high. His group is working to leverage quantitative characteristics of the nodule and the lung that are apparent on the CT scan to distinguish lung cancers from the many benign lung nodules that are detected, and thus to decide which patients should proceed to biopsy. Under the mentorship of Dr. Jason Bates of the Division of Pulmonary and Critical Care, advanced computational modeling is then used to understand how to apply these CT characteristics to the personalized decision of which individual should undergo a biopsy.
A major focus of the laboratory is on the development and correct selection of therapies for lung cancer. Lung cancers are heterogeneous and some respond more readily to one therapy vs. another. Dr. Kinsey uses small tissue biopsies obtained during advanced bronchoscopic and thoracic procedures through his clinical work as an Interventional Pulmonologist to develop systems for evaluating what therapies an individual’s cancer may respond to. A focus of this work includes evaluation for treatment with direct therapy of the tumor - e.g. treating a lung cancer from the airway with the goal of improving the response to systemic therapies. Dr. Kinsey was one of the first in the US to begin treating tumors by injecting cisplatin, a chemotherapeutic agent, directly into a tumor to achieve these therapeutic goals. 1. Kinsey CM, Estepar RS, Van der Velden J, Cole BF, Christiani DC, Washko GR. Lower Pectoralis Muscle Area is Associated with a Worse Overall Survival in Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 26(1):38-43 (2017). PMID: 27197281
2. Kinsey, CM, Hamlington, KL, O'Toole, J, Stapleton, R, & Bates, JHT. (2016). Predicting the Mortality Benefit of CT Screening for Second Lung Cancer in a High-Risk Population. PLoS ONE, 11(11), e0165471. (2016). PMID 27806080
3. Kinsey CM and Ost D. Randomization in Diagnostic and Therapeutic Interventional Pulmonary Trials. Journal of Bronchology and Interventional Pulmonology. 23(4), 272–278. (2016). PMID 27764005
4. Khan F, Garrison G, Anker C, and Kinsey CM. “Endobronchial ultrasound guided-transbronchial needle injection (EBUS-TBNI) for local control of recurrent non-small cell lung cancer”. Ann Am Thorac Soc 12(1):101-4 (2014) PMID: 25513850
5. Kinsey CM and Arenberg DA. Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Non-Small Cell Lung Cancer Staging. Am J Respir Crit Care Med 189(6):640-649 (2014). PMID: 24598367